Stem Cell Treatment for Stroke Rehabilitation

Every 40 seconds, someone in the United States has a stroke. Every year, nearly 800,000 Americans join the global population of 80 million stroke survivors — people living with the aftermath of a sudden disruption to blood supply in the brain.

For many of them, the hardest part is not the stroke itself. It is what comes after.

The arm that won't cooperate. The leg that drags. The words that come out wrong, or don't come at all. Rehabilitation works — physical therapy, speech therapy, occupational therapy — but it works best in the weeks and months immediately following the event, when the brain is in its most plastic, most receptive state. After that window closes, the conventional medical consensus has long been: what remains, remains. Deficits that persist beyond the first year are, for practical purposes, permanent.

That consensus is being challenged. Not by wishful thinking, but by a decade of increasingly rigorous clinical evidence showing that stem cells — introduced into the brain months or years after a stroke — can trigger recovery in patients whose deficits had been considered stable and irreversible.

Understanding Stroke and Its Aftermath

A stroke occurs when blood flow to part of the brain is interrupted — either by a clot blocking an artery (ischemic stroke, accounting for approximately 87% of all strokes) or by a ruptured blood vessel causing bleeding into or around the brain (hemorrhagic stroke). Within minutes of blood flow interruption, neurons in the ischemic core begin to die. Within hours, the zone of damage expands into the surrounding penumbra — the region of brain tissue that is compromised but not yet dead.

The acute treatment window is narrow. Intravenous thrombolysis (tPA) must be administered within 4.5 hours of symptom onset. Mechanical thrombectomy can extend the window somewhat further for certain large vessel occlusions. Both treatments aim to restore blood flow before irreversible infarction is complete.

What neither treatment addresses is the brain tissue that has already been lost — or the functional deficits that persist after the acute phase. The infarcted brain does not spontaneously regenerate neurons. The motor cortex, language areas, and other regions affected by the stroke undergo a reorganization process — neuroplasticity — but this is limited in extent and in duration.

The result: an estimated 50% of stroke survivors have persistent physical disability at six months. Up to 30% experience long-term severe disability. Depression, cognitive impairment, and communication disorders add to the burden. For these patients, conventional rehabilitation offers incremental gains — and, at some point, stops offering more.

What Stem Cell Therapy Aims to Do

Stem cell therapy for stroke does not aim to rebuild the infarcted brain tissue directly. The goal is more nuanced and, in many ways, more achievable: to activate and amplify the brain's own residual regenerative capacity, enhance neuroplasticity in the surviving tissue surrounding the infarct (the peri-infarct zone), and restore neural circuit function through mechanisms that standard rehabilitation cannot access.

The key mechanisms, as understood from both preclinical and clinical research, include:

Neuroplasticity enhancement

The peri-infarct zone — the surviving brain tissue surrounding the stroke injury — remains capable of functional reorganization for a period following stroke, but this capacity diminishes over time. Stem cells, particularly those derived from neural or mesenchymal sources, produce neurotrophic factors (BDNF, VEGF, GDNF, NGF) that reactivate this plastic potential — essentially reopening the neuroplasticity window in chronically affected brain tissue.

Cortical excitability restoration

Research published in Molecular Therapy in December 2024 by scientists at Gladstone Institutes and SanBio showed that modified stem cells restore normal patterns of cortical excitability — the electrical signaling patterns underlying brain function — in rats following ischemic stroke, even when administered a month after the stroke event. The disruption of excitatory-inhibitory balance in peri-infarct cortex is a key mechanism of chronic motor deficit; restoring that balance is mechanistically linked to clinical motor recovery.

Anti-inflammatory neuroprotection

Chronic low-grade neuroinflammation persists for months to years after ischemic stroke, contributing to ongoing neuronal dysfunction in the peri-infarct zone. Stem cells — particularly MSCs — actively modulate this environment by suppressing pro-inflammatory microglia and macrophage activity, reducing cytokine-mediated neuronal injury, and creating a more permissive environment for recovery.

Angiogenesis and vascular remodeling

Stem cell-derived VEGF and other angiogenic factors promote the formation of new blood vessels in the peri-infarct zone, improving the local delivery of oxygen and nutrients to compromised-but-surviving neurons and supporting the metabolic demands of neuroplasticity.

Synaptogenesis and circuit reconstruction

Some cell types — particularly neural stem cells — can integrate into existing neural circuits, forming new synaptic connections that partially reconstruct disrupted pathways. The degree to which transplanted cells actually differentiate and integrate versus acting primarily through paracrine mechanisms is still being defined, but both contribute to functional recovery.

The Clinical Evidence

The clinical evidence base for stem cell therapy in stroke rehabilitation is now substantial — spanning multiple Phase 1, Phase 2, and Phase 2/3 trials, with increasingly rigorous designs including randomization and sham surgery controls.

NR1 Neural Stem Cell Trial — Stanford University (Phase 1/2a)

The most compelling recent data comes from the first-in-human Phase 1/2a trial of NR1 — a human embryonic stem cell-derived neural stem cell therapy developed by the Steinberg laboratory at Stanford — investigating intracerebral transplantation in chronic ischemic stroke patients.

Eighteen patients were enrolled (6 to 60 months post-stroke, modified Rankin Score 3–4, subcortical MCA territory stroke). NR1 cells were delivered stereotactically into the subcortical peri-infarct area through a small burr hole under local anesthesia, at doses escalating from 2.5 to 20 million cells. Immunosuppression with tacrolimus was administered for 8 weeks.

Results presented at the American Association of Neurological Surgeons 2024 Annual Meeting and published as an abstract in Stroke:

• Average improvement of 7.3 points on the upper-extremity Fugl-Meyer Assessment (FMA) at 12 months
• Average improvement of 4.5 points on the lower-extremity FMA at 12 months
• 8 of 12 evaluable patients showed a ≥10-point improvement in total Fugl-Meyer Motor Score — the threshold considered clinically meaningful
• Notably, improvement continued to accumulate between 6 and 12 months — an observation that investigators described as unprecedented in prior transplant trials, with an 11.8-point average improvement in total motor score at 12 months versus 9.3 points at 6 months
• No serious adverse events attributable to the cell therapy

Professor Gary Steinberg (Stanford co-director of the Stroke Center): "Their ability to move around has recovered visibly. That's unprecedented."

Crucially, NR1 cells are not genetically modified — addressing a key safety concern with other neural stem cell products that require genetic manipulation and carry a theoretical oncogenic risk.

SanBio SB623 — Phase 2b and STEMTRA Trial

SB623 is a modified MSC product (bone marrow-derived MSCs transiently modified with a Notch intracellular domain construct) developed by SanBio. It has been investigated across multiple clinical trials in both chronic ischemic stroke and traumatic brain injury.

The Phase 2b SB-STR02 trial was a randomized, double-blind, sham surgery-controlled trial of SB623 in patients with chronic stroke (>6 months post-stroke, up to 7.5 years). SB623 cells were implanted in the peri-infarct region at doses of 2.5 or 5 million cells. Results showed clinically meaningful improvements in Fugl-Meyer Motor Score at 6 months in treated patients.

Extending this evidence, the STEMTRA Phase 2 trial — a randomized, double-blind, surgical sham-controlled international multicenter trial — evaluated SB623 in chronic traumatic brain injury patients with motor deficits. Published in Neurology (September 2024), STEMTRA demonstrated sustained improvement in Fugl-Meyer Motor Scale scores up to 48 weeks post-implantation, with associated improvement in activities of daily living — reinforcing the durability of motor recovery produced by intracerebral MSC implantation in chronic neurological injury.

The Gladstone Institutes' December 2024 Molecular Therapy publication, which mechanistically characterized how SB623-like modified MSCs restore cortical excitability, directly addresses the previously unknown biological pathway connecting cell therapy to motor improvement — a critical step in understanding why the clinical results are what they are.

TREASURE Phase 2/3 — Allogeneic Stem Cell Therapy for Acute Ischemic Stroke

Published in JAMA Neurology (2024), the TREASURE trial was a Phase 2/3 randomized controlled trial evaluating allogeneic stem cell therapy in acute ischemic stroke. The study represents the advancement of cell therapy evaluation from chronic to acute stroke settings, with results contributing to the growing multi-phase evidence architecture supporting this field.

Network Meta-Analysis — 19 Studies, 1,055 Patients (BMC Neurology, May 2025)

A comprehensive network meta-analysis published in BMC Neurology in May 2025 evaluated 19 studies and 1,055 patients comparing five stem cell types in ischemic stroke rehabilitation: bone marrow mononuclear cells (BMMNCs), bone marrow MSCs (BMMSCs), progenitor cells, peripheral blood stem cells, and others. The analysis found statistically significant improvements in neurological function outcomes across multiple cell types, providing the largest systematic evidence synthesis to date for the field.

Cell Types Used in Stroke Rehabilitation

Neural Stem Cells (NSCs) — NR1 Derived from human embryonic stem cells and differentiated into neural progenitors. These cells are most biologically aligned with the tissue they are intended to repair — brain neural tissue — and are capable of both paracrine neuroprotective activity and potential synaptic integration. NR1 is non-genetically modified, addressing the safety concerns that limited earlier neural stem cell programs.

Modified MSCs — SB623 (SanBio) Bone marrow-derived MSCs transiently modified to enhance neurotropic and neuroplasticity-promoting properties. Their primary mechanism is paracrine — through neurotrophic factor secretion and cortical excitability modulation — rather than neural differentiation. Extensive clinical trial history across stroke and TBI.

Unmodified MSCs (BM-MSCs, UC-MSCs) Standard mesenchymal stem cells from bone marrow or umbilical cord. Their role in stroke is primarily immunomodulatory and neurotrophic. Delivery via intravenous or intra-arterial infusion allows non-surgical administration, which expands the patient population that can be considered. Multiple clinical trials have shown safety and neurological improvement signals with IV/IA MSC delivery.

Bone Marrow Mononuclear Cells (BMMNCs) A heterogeneous cell fraction from bone marrow including MSCs, hematopoietic progenitors, and endothelial progenitors. Studied primarily in acute and subacute stroke settings (IBIS trial). Easier to prepare than purified or cultured MSC products.

The Treatment Process

The delivery approach depends on the cell type being used and the timing of treatment:

Intracerebral Stereotactic Implantation Used for neural stem cells (NR1) and modified MSCs (SB623). Under local anesthesia, a small burr hole is made in the skull and cells are injected stereotactically — with neurosurgical precision — into the subcortical peri-infarct zone. Patients are awake during the procedure and typically discharged the following day. This approach delivers cells directly to the target tissue but requires neurosurgical expertise and patient fitness for the procedure.

Intravenous or Intra-arterial Infusion Used for unmodified MSCs and BMMNCs. IV or IA administration is non-surgical, broadens the eligible patient population, and leverages the cells' capacity for homing to sites of neurological injury through chemotactic signals. Delivery is simpler but cell distribution to the brain is less targeted than direct implantation.

Post-Procedure Rehabilitation All stem cell programs for stroke emphasize that cell therapy is not a replacement for rehabilitation — it is an adjunct that enhances the brain's responsiveness to it. Physical therapy, occupational therapy, and speech therapy initiated in conjunction with cell therapy are critical for converting the neuroplastic changes induced by cell therapy into functional gains.

Who Is a Candidate?

Based on current clinical trial experience, the profile of patients most commonly evaluated includes:

• Confirmed ischemic stroke (hemorrhagic stroke indications are less developed)
• Chronic stroke phase: typically 6 months or more post-event with stable, persistent motor deficits
• Moderate-to-severe functional deficit (modified Rankin Score 3–4, Fugl-Meyer motor impairment in the range targeted by trials)
• Subcortical involvement of the relevant motor pathways (cortical and large, entirely cystic infarcts present more challenges for peri-infarct delivery approaches)
• Adequate overall health for the chosen delivery approach
• No active malignancy, severe cardiac or renal disease, or other major contraindications

Earlier-phase (acute and subacute) stroke programs are also under investigation. Individual evaluation is essential — stroke lesion anatomy, location, and size are directly relevant to which approach is most appropriate.

Frequently Asked Questions

Is it too late to benefit if my stroke was several years ago? The NR1 trial enrolled patients up to 60 months post-stroke, and the SB623 Phase 2b trial enrolled patients up to 7.5 years post-event. Clinical benefit has been demonstrated at both shorter and longer intervals. The key factor is not time elapsed but the viability of the peri-infarct zone as a target for neuroplasticity enhancement — which individual brain imaging can help assess.

Does this require brain surgery? The intracerebral implantation approach (NR1, SB623) does involve a minimally invasive neurosurgical procedure — a small burr hole under local anesthesia. Patients in the NR1 trial were awake throughout and discharged the following day. IV or IA delivery approaches (unmodified MSCs) are non-surgical. The appropriate delivery method depends on cell type and clinical protocol.

Will I need immunosuppression? For allogeneic cell products, a course of immunosuppressive medication is typically administered for a defined period (8 weeks in the NR1 trial, using tacrolimus). Autologous approaches do not require this. The immunosuppression requirement is temporary and well-tolerated in most patients.

How much improvement can be expected? The NR1 trial showed an average 7.3-point improvement in upper-extremity Fugl-Meyer score at 12 months. For context, the minimum clinically important difference for this scale is approximately 6 points — meaning the average improvement exceeded the threshold for a meaningful clinical change. Individual responses varied, with some patients showing substantially larger gains. Stem cell therapy does not restore the brain to its pre-stroke state; it offers functional improvement above the stable chronic deficit baseline.

Can this be combined with ongoing rehabilitation? Yes — and it should be. The clinical trials consistently support the integration of physical and occupational therapy alongside and following cell therapy. The cells create a neuroplastic environment; rehabilitation directs that neuroplasticity into functional improvements. The combination is more effective than either alone.

What happens after 12 months — do the benefits persist? The NR1 trial data showed continued improvement between 6 and 12 months — an unusual finding that suggests the neuroplastic changes induced by the treatment continue to mature over time. The SB623 STEMTRA data showed sustained improvement to 48 weeks. Long-term data beyond two years is still accumulating.

A New Chapter in Stroke Medicine

For decades, the framework for stroke rehabilitation has been built around a simple and discouraging premise: the brain can reorganize after a stroke, but it cannot regenerate. Rehabilitation exploits the reorganization; nothing addresses the regeneration.

The clinical evidence accumulated over the past decade — from the earliest Stanford SB623 trials through the 2024 NR1 data presented at the AANS — is systematically eroding that premise. Not with large-population Phase 3 approval data yet, but with consistent signals from rigorous Phase 1 and Phase 2 trials showing that patients who were stable, plateau-ed, sometimes years past their stroke, improved meaningfully after receiving stem cell therapy.

The brain, it turns out, is not as finished with recovery as medicine assumed.

For stroke survivors living with deficits that conventional rehabilitation has taken as far as it will go, the question of whether stem cell therapy offers a next step is worth asking seriously.

Contact our team to discuss whether you or your family member may be a candidate for stem cell therapy and what the current evidence means for your specific situation.

This article is for informational purposes only and does not constitute medical advice. Stroke management and rehabilitation should always be supervised by qualified neurological and rehabilitation specialists.